Description
PP42 Th17 impact on xenogeneic graft-versus-host disease
Article: PP42 Th17 impact on xenogeneic graft-versus-host disease
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in melanoma
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart
